Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults

AIDS

Volumn 29, Issue 2, 2015, Pages 175-182

  Erlandson, Kristine M ^a   Jiang, Ying ^b   Debanne, Sara M ^b   McComsey, Grace A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Body fat; Bone mineral density; HIV; Lean body mass; Statin

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VIRUS RNA; BIOLOGICAL MARKER; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ADULT DISEASE; ANTIVIRAL THERAPY; ARTICLE; ATHEROSCLEROSIS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAT MASS; FEMALE; FOLLOW UP; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LEAN BODY WEIGHT; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MYALGIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHYDRATION; RHABDOMYOLYSIS; BLOOD; BODY COMPOSITION; CARDIOVASCULAR DISEASES; DRUG EFFECTS; HIV INFECTIONS; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK FACTOR;

ABSORPTIOMETRY, PHOTON; ADULT; BIOMARKERS; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASES; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OSTEOPOROSIS; PYRIMIDINES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REGRESSION ANALYSIS; RISK FACTORS; ROSUVASTATIN CALCIUM; SULFONAMIDES;

EID: 84920270496     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000526     Document Type: Article

References (39)

1. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Topics HIV Med 2009; 17:118-123.
2. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542-553.
3. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006; 97:33a-41a.
4. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209:1156-1164.
5. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588-595.
6. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56:1471-1479.
7. Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study. AIDS 2006; 20:1003-1010.
8. Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort. Antivir Ther 2009; 14:853-858.
9. Riechman SE, Andrews RD, Maclean DA, Sheather S. Statins and dietary and serum cholesterol are associated with increased lean mass following resistance training. J Gerontol A Biol Sci Med Sci 2007; 62:1164-1171.
10. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007; 55:420-425.
11. Erlandson KM, O'Riordan M, Labbato D, McComsey GA. Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr 2014; 65:290-298.
12. Longenecker CT, Funderburg NT, Jiang Y, Debanne S, Storer N, Labbato DE, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385-390.
13. Assessment of fracture risk and its application to screening for postmenopausal, osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
14. Funderburg NT, Clagett B, Jiang Y, Debanne S, Storer N, Labbato D, et al. Rosuvastatin reduces immune activation and inflammation in treated HIV infection [Poster 335]. Conference on Retroviruses and Opportunistic Infections; 2014; Boston, MA.
15. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21:2473-2482.
16. Ruan F, Zheng Q, Wang J. Mechanisms of bone anabolism regulated by statins. Biosci Rep 2012; 32:511-519.
17. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286:1946-1949.
18. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001; 287:337-342.
19. Han G, Chen Y, Hou J, Liu C, Chen C, Zhuang J, et al. Effects of simvastatin on relapse and remodeling of periodontal tissues after tooth movement in rats. Am J Orthod Dentofacial Orthop 2010; 138:550.
20. Ayukawa Y, Yasukawa E, Moriyama Y, Ogino Y, Wada H, Atsuta I, et al. Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107:336-342.
21. Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB. Simvastatin 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 2008; 123:1733-1740.
22. Ochi H, Hara Y, Tagawa M, Shinomiya K, Asou Y. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival. J Orthop Res 2010; 28:657-663.
23. Abu-Amer Y, Abbas S, Hirayama T. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. J Cell Biochem 2004; 93:980-989.
24. Liu J, Zhu LP, Yang XL, Huang HL, Ye DQ. HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis. Bone 2013; 54:151-156.
25. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164:146-152.
26. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003; 139:97-104.
27. Calmy A, Bloch M, Wand H, Delhumeau C, Finlayson R, Rafferty M, et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010; 11:493-501.
28. Yokoyama H, Saito S, Daitoku K, Fukuda I, Higuma T, Hanada H, et al. Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease. Fundam Clin Pharmacol 2011; 25:378-387.
29. Kai T, Arima S, Taniyama Y, Nakabou M, Kanamasa K. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. Clin Exp Hypertens 2008; 30:530-540.
30. Hernandez-Vallejo SJ, Beaupere C, Larghero J, Capeau J, Lagathu C. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell 2013; 12:955-965.
31. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137:581-585.
32. Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 2009; 102:625-633.
33. Dzien A, Winner H, Theurl E, Dzien-Bischinger C, Lechleitner M. Fat-free mass and fasting glucose values in patients with and without statin therapy assigned to age groups between <60 and >75 years. Obes Facts 2013; 6:9-16.
34. Ballard KD, Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis 2013; 230:121-124.
35. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96-103.
36. Parker BA, Capizzi JA, Augeri AL, Grimaldi AS, Michael White C, Thompson PD. Atorvastatin increases exercise leg blood flow in healthy adults. Atherosclerosis 2011; 219:768-773.
37. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107:757-761.
38. Gray SL, Aragaki AK, LaMonte MJ, Cochrane BB, Kooperberg C, Robinson JG, et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc 2012; 60:2206-2214.
39. Giri J, McDermott MM, Greenland P, Guralnik JM, Criqui MH, Liu K, et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 2006; 47:998-1004.